These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35974805)

  • 1. Carbapenemase Inhibitors: Updates on Developments in 2021.
    Bou Zerdan M; Al Hassan S; Shaker W; El Hajjar R; Allam S; Bou Zerdan M; Naji A; Zeineddine N
    J Clin Med Res; 2022 Jul; 14(7):251-259. PubMed ID: 35974805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.
    Vázquez-Ucha JC; Arca-Suárez J; Bou G; Beceiro A
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
    Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM
    ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985
    [No Abstract]   [Full Text] [Related]  

  • 6. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.
    Bouza E
    J Antimicrob Chemother; 2021 Nov; 76(Suppl 4):iv38-iv45. PubMed ID: 34849998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
    Bhowmick T; Weinstein MP
    Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem/vaborbactam activity
    Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.
    Gaibani P; Giani T; Bovo F; Lombardo D; Amadesi S; Lazzarotto T; Coppi M; Rossolini GM; Ambretti S
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
    Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
    Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenemase producing
    Karaiskos I; Galani I; Papoutsaki V; Galani L; Giamarellou H
    Expert Rev Anti Infect Ther; 2022 Jan; 20(1):53-69. PubMed ID: 34033499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-lactam/β-lactamase inhibitor combinations: from then to now.
    Toussaint KA; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):86-98. PubMed ID: 25361682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.